bioengineer.org
Faecalibacterium prausnitzii Trial for Crohn's Disease Remission - Bioengineer.org
This study tests a live Faecalibacterium prausnitzii probiotic (EXL01) as a way to prolong steroid-induced remission in Crohn’s disease, a potential new strategy to reduce relapses and steroid exposure.
Early trial results reported longer remission and favorable microbiome changes, which could matter to patients looking for maintenance options with fewer systemic side effects.
Adults with Crohn’s disease, clinicians caring for IBD patients, researchers in microbiome therapeutics, and people interested in microbiome-based maintenance strategies.
What To Know
What to know This article reports a first-in-human randomized, double-blind, placebo-controlled trial of a stabilized Faecalibacterium prausnitzii probiotic formulation (EXL01) given to adults with Crohn’s disease who recently achieved steroid-induced response or remission.
The trial evaluated clinical remission duration, objective inflammation markers (CRP and endoscopy), and microbiome changes, and found longer remission and increased F. prausnitzii abundance in treated participants with no serious probiotic-attributed adverse events reported. The formulation was engineered to address F.
prausnitzii’s extreme oxygen sensitivity through stabilization and packaging techniques to preserve viability. Microbiome sequencing and short-chain fatty acid measurements were used as secondary endpoints to link biological changes to clinical outcomes. What this means for patients This is an early-stage clinical trial (pilot/first-in-human).
Results are promising but preliminary: they suggest the probiotic may help maintain steroid-induced remission and increase beneficial gut metabolites, yet the study authors note small sample size and short follow-up. Larger, longer trials are needed before this becomes a standard treatment option.
Next steps and caveats Readers should view this as encouraging research rather than an approved therapy. Future multi-center studies and investigations of EXL01 in combination with existing IBD treatments will be important to determine safety, durability of effect, and where a probiotic like EXL01 might fit into Crohn’s disease management.
The article describes a first-in-human randomized pilot trial with limited sample size and short follow-up. Findings are preliminary and require confirmation in larger, longer randomized trials before changing clinical practice.
The publication in Nature Communications suggests peer-reviewed reporting, but details like exact sample size, timeline, and statistical endpoints were not included in this summary.
